Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)

Trial Profile

Description of the Use of fidAxomicin in Hospitalized Patients With Documented Clostridium diFficile iNfection and of the managEment of These Patients (DAFNE Study)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Jul 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fidaxomicin (Primary)
  • Indications Clostridium difficile infections
  • Focus Therapeutic Use
  • Acronyms DAFNE
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 01 Jun 2021 Results (n=294) assessing the characteristics, management and outcomes of hospitalised patients with clostridium difficile infection who were treated with fidaxomicin and also describes the management of patients with CDI who did not receive fidaxomicin, published in the Journal of International Medical Research.
    • 11 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 26 Sep 2017 Planned End Date changed from 1 Jul 2017 to 1 Sep 2017.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top